US 12,487,243 B2
Method of diagnosis of infection by the SARS-CoV-2 virus
Thierry Poynard, Paris (FR); Patrice Cacoub, Nogent sur Marne (FR); and Olivier Deckmyn, Cabries (FR)
Assigned to BIOPREDICTIVE, Paris (FR); and ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, Paris (FR)
Appl. No. 17/999,922
Filed by BIOPREDICTIVE, Paris (FR); and ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, Paris (FR)
PCT Filed May 26, 2021, PCT No. PCT/EP2021/064034
§ 371(c)(1), (2) Date Nov. 27, 2022,
PCT Pub. No. WO2021/239803, PCT Pub. Date Dec. 2, 2021.
Claims priority of application No. 20305553 (EP), filed on May 27, 2020; and application No. 20306650 (EP), filed on Dec. 21, 2020.
Prior Publication US 2023/0236197 A1, Jul. 27, 2023
Int. Cl. G01N 33/68 (2006.01); A61K 45/06 (2006.01)
CPC G01N 33/6827 (2013.01) [A61K 45/06 (2013.01); G01N 33/6893 (2013.01)] 5 Claims
OG exemplary drawing
 
1. An in vitro method for detecting whether a patient is infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) virus, comprising:
a) determining an amount of apolipoprotein A1 (apoA1) in a serum sample from the patient and additionally assessing other clinical markers of the patient to obtain values, wherein
measurement of the amount of apoAI is performed by at least one of the following methods: ELISA, colorimetric assay, or Lateral Flow Assay, and
the other clinical markers are an amount of gammaglutamyl transpeptidase (GGT), an amount of haptoglobin (Hapto), an amount of a2-macroglobulin (A2M), age of the patient, and sex of the patient;
b) combining the amount of apoA1 and the values obtained in a) through a function and calculating an end value, wherein the function is F6=a0+a1*ApoA1 (g/L)+a2*Log (hapto (g/L))+a3 Log (*GGT (IU/L))+a4*Log (A2M (g/L))+a5*Log (AGE (years))+a6*SEX (0 for women, 1 for men), with
i) −23≤a0≤−19,
ii) −11.2≤a1≤−8.4,
iii) 4.5≤a2≤7.7,
iv) 2.3≤a3≤4.2,
v) −0.75≤a4≤−0.25,
vi) 11.5≤a5≤15.5, and
vii) −1.8≤a6≤−0.5; and
c) comparing the end value calculated in b) to a predetermined threshold, wherein the patient is infected with the SARS-Cov-2 if the end value calculated in b) is higher than the threshold.